The ECLIPSE Study： Efficacy of cryoablation on metastatic lung tumors with a 5-year follow-up

（JOURNAL OF THORACIC ONCOLOGY；IF：15。609）

De Baère T， Woodrum D， Tselikas L， et al。 The ECLIPSE Study： Efficacy of cryoablation on metastatic lung tumors with a 5-year follow-up。 J Thorac Oncol 2021。

CORRESPONDENCE TO ： thierry。debaere@gustaveroussy。fr

Introduction 引言

The ECLIPSE study aimed to assess the feasibility and efficacy of cryoablation for local tumor control in patients with pulmonary metastatic disease over five years of follow-up。

ECLIPSE 研究旨在評估冷凍消融術在五年隨訪中對肺轉移性疾病患者區域性腫瘤控制的可行性和有效性。

Methods 方法

ECLIPSE was a prospective， multicenter， single-arm study which included patients treated with cryoablation if they had 1-5 metastatic lung tumors， each with a diameter of ≤ 3。5 cm。 Patients were followed up over the course of five years。 The primary endpoint was local tumor control， both per tumor and per patient； secondary endpoints included cancer-specific survival， overall survival （OS）， and quality of life。 Quality of life was assessed using the Karnofsky Performance Score， the Eastern Cooperative Oncology Group Performance Score， and the Short Form-12 health survey。

ECLIPSE 是一項前瞻性、多中心、單臂研究，納入了接受冷凍消融治療的患者，若他們有 1-5 個轉移性肺腫瘤且每個病灶直徑≤ 3。5 cm。我們對患者進行了為期五年的隨訪。主要終點是每個腫瘤和每個患者的區域性腫瘤控制；次要終點包括癌症特異性生存率、總生存率 （OS） 和生活質量。生活質量由Karnofsky Performance評分、Eastern Cooperative Oncology Group Performance評分和 Short Form-12 健康調查進行評估。

Results 結果

The study included 40 patients across 4 sites （3 US and 1 European）。 A total of 60 metastatic pulmonary tumors were treated with 48 cryoablation procedures。 Overall local tumor control rates were 87。9% （29/33） and 79。2% （19/24） per tumor， and 83。3% （20/24） and 75。0% （15/20） per patient， at 3 and 5 years respectively。 A total of 5 treated patients demonstrated local progression throughout the duration of the study。 Disease specific survival rate was of 74。8% at 3 years and 55。3% at 5 years while overall survival at 3 and 5 years were of 63。2% and 46。7% respectively。 Patient quality of life scores did not reach statistical significance。

該研究包括來自 4 個地點（3 個美國和 1 個歐洲）的 40 名患者。總共 60 個轉移性肺腫瘤接受了 48 次冷凍消融手術。在 3 年和 5 年時，每個腫瘤的總體區域性腫瘤控制率分別為 87。9% （29/33） 和 79。2% （19/24），每個患者分別為 83。3% （20/24） 和 75。0% （15/20）。在整個研究期間，共有 5 名接受治療的患者出現區域性進展。3 年疾病特異性生存率為 74。8%，5 年為 55。3%，而 3 年和 5 年總生存率分別為 63。2% 和 46。7%。患者生活質量評分未達到統計學意義。

Conclusions 結論

Cryoablation is an effective means of long-term local tumor control in patients with metastatic pulmonary tumors。

冷凍消融是轉移性肺腫瘤患者長期區域性腫瘤控制的有效手段。